Department of Medicine I, Medical University of Vienna, Comprehensive Cancer Center-Central Nervous System Tumors Unit (CCC-CNS), Vienna, Austria; Institute of Radiation Oncology, Kaiser-Franz-Josef Hospital, Vienna, Austria; MedAustron Ion Therapy Center, Wiener Neustadt, Austria.
MedAustron Ion Therapy Center, Wiener Neustadt, Austria.
Radiother Oncol. 2017 Nov;125(2):228-233. doi: 10.1016/j.radonc.2017.07.027. Epub 2017 Aug 8.
The importance of QoL and neurocognitive functions in patients with glioblastoma (GB) is above controversy by now. We followed newly diagnosed GB patients treated with radio-chemotherapy during their course of disease by continuously evaluating their quality of life (QoL) and cognitive functions.
We included consecutive patients with newly diagnosed GB from 2010 to 2013 at the Medical University of Vienna. To assess QoL the EORTC QLQ C30 and BN20 questionnaire were used. Neurocognition was measured with the NeuroCog FX. The evaluations were done 6 times every three months, beginning at the beginning of radio-chemotherapy.
42 patients participated in this study. We also recorded QoL and neurocognition in 23 patients after the first disease progression. Patients maintained their cognitive summary score until relapse. Patients with left-sided tumors showed significant lower scores in the subscale verbal fluency than patients with right-sided tumors. The global health score of QoL decreased after the fifth evaluation (13months after diagnosis) whereas a peak of fatigue symptoms was obtained at the third evaluation. Furthermore, fatigue symptoms increased strongly 7months after diagnosis and patients' financial difficulties were mentioned more frequently by younger patients and in patients with lower education levels.
QoL and cognitive long-term assessments are feasible also in some patients with GB after a symptomatic progression. Our study demonstrates maintenance of QoL and cognitive summary scales before tumor progression. Moreover, it highlights subgroups according to tumor location and socioeconomic factors.
目前，生活质量（QoL）和神经认知功能在胶质母细胞瘤（GB）患者中的重要性已毋庸置疑。我们通过连续评估新诊断的胶质母细胞瘤患者在疾病过程中的生活质量（QoL）和认知功能，对接受放化疗的患者进行随访。
我们纳入了 2010 年至 2013 年期间维也纳医科大学新诊断为胶质母细胞瘤的连续患者。为了评估 QoL，使用了 EORTC QLQ C30 和 BN20 问卷。神经认知功能使用 NeuroCog FX 进行测量。评估在放化疗开始时每三个月进行 6 次，共进行 6 次。
42 名患者参与了这项研究。我们还在 23 名患者首次疾病进展后记录了 QoL 和认知功能。患者在复发前保持认知综合评分。左侧肿瘤患者在言语流畅性亚量表中的得分明显低于右侧肿瘤患者。QoL 的全球健康评分在第五次评估（诊断后 13 个月）后下降，而疲劳症状在第三次评估时达到峰值。此外，诊断后 7 个月疲劳症状明显加重，年轻患者和受教育程度较低的患者更频繁地提到经济困难。
在出现症状进展后，一些胶质母细胞瘤患者也可以进行 QoL 和认知的长期评估。我们的研究表明，在肿瘤进展前 QoL 和认知综合评分保持稳定。此外，它还根据肿瘤位置和社会经济因素突出了亚组。
